Pilot Study of Haloperidol to Treat Critical Illness Delirium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00429676
Recruitment Status : Completed
First Posted : February 1, 2007
Last Update Posted : November 14, 2012
Denver Health Medical Center
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The goal of this study is to determine whether haloperidol reduces the time on the breathing machine in critically ill patients with delirium.

Condition or disease Intervention/treatment Phase
Delirium Critical Illness Drug: Haloperidol Phase 2

Detailed Description:

Delirium is a frequent end-organ complication of critical illness and is an independent predictor of mortality in mechanically ventilated patients. However, management of delirium is a major therapeutic challenge and it is unknown if current therapies are disease modifying or function only as symptom management. Haloperidol has been demonstrated to reduce delirium in retrospective studies.

This study is a pilot prospective randomized clinical trial in the Denver Health Medical ICU to determine if haloperidol in addition to an evidence-based standard-of-care sedation protocol for the management of delirium results in a shortened duration of intubation and improvements in post-extubation cognitive status. The haloperidol dose is administered using titration-protocol guided by nursing assessment of delirium using the confusion assessment method for the ICU (CAM-ICU). The primary outcome is ventilator-free days out of the first 28, and secondary outcomes include duration of delirium, length and cost of hospitalization, 28-day mortality, usage of other sedatives, serum markers of delirium (neuron-specific enolase and protein S-100B), and cognitive-function scores at the time of ICU discharge, hospital discharge, and six-month follow-up.

The goal of the 20-patient pilot is demonstrating safety of the haloperidol protocol, as evaluated by an independent data-safety monitoring board. Following approval of the DSMB, 122 more patients will be enrolled in the full RCT to achieve power for an 80% chance of detecting a 40% decrease in duration of intubation with P < 0.05.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium
Study Start Date : December 2005
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Delirium

Primary Outcome Measures :
  1. Ventilator-free days out of the first 28

Secondary Outcome Measures :
  1. Duration of delirium
  2. Length of hospitalization
  3. Cost of hospitalization
  4. 28-day mortality
  5. Usage of other sedatives
  6. Serum markers of delirium (neuron-specific enolase and protein S-100B)
  7. Cognitive-function scores at the time of ICU discharge, hospital discharge, and six-month follow-up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mechanically ventilated within 24 hours of arrival to the ICU
  • Delirium as assessed by CAM-ICU within 24 hours of arrival to the ICU
  • Age > 18

Exclusion Criteria:

  • Known allergy to haloperidol or other neuroleptics
  • Neurological injury or trauma
  • < 24 hours after a major operation
  • History of Axis I psychiatric disorder or significant dementia
  • Baseline QTc of > 500 msec or a pacemaker which makes the QTc uninterpretable
  • History of seizure disorder
  • Morbid obesity (> 1kg/cm body weight)
  • Hepatic failure (Child's Class C)
  • Neuromuscular disease (C5 or higher spinal cord injury, ALS, Guillain-Barre Syndrome, and myasthenia gravis)
  • Malignancy or other irreversible disease or condition for which 6 month mortality is estimated to be ≥ 50%
  • Pregnancy (negative pregnancy test required for women of child-bearing potential)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00429676

United States, Colorado
Denver Health Medical Center
Denver, Colorado, United States, 80204
Sponsors and Collaborators
University of Colorado, Denver
Denver Health Medical Center
Principal Investigator: Ivor S Douglas, MD University of Colorado Department of Pulmonary and Critical Care Medicine

Responsible Party: University of Colorado, Denver Identifier: NCT00429676     History of Changes
Other Study ID Numbers: 05-0362
First Posted: February 1, 2007    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: November 2009

Keywords provided by University of Colorado, Denver:

Additional relevant MeSH terms:
Critical Illness
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Disease Attributes
Pathologic Processes
Haloperidol decanoate
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents